Navigation Links
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
Date:1/6/2014

ng the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, development progress of the Company's companion diagnostics, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of the Company's 10-Q filed with the Securities and Exchange Commission on October 23, 2013. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
2. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
3. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
6. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
7. Advanced Biofuels USA's Joanne Ivancic Recognized as One of Top 100 People in the BioEconomy by Biofuels Digest
8. Westchase Neck Injury Chiropractor is Now Offering the Newest Advanced Care Treatments for Injury and Chronic Pain, Courtesy of Elan Wellness Center
9. ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
10. New Ocean Sensing and Monitoring Brings Tutorial Approach to Latest Advances
11. Phoenix Research Labs Partners with Voxeleron to Advance Technology for Eye Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Investor-Edge has initiated coverage on ... GENE ), Agilent Technologies Inc. (NYSE: A ... ), Sequenom Inc. (NASDAQ: SQNM ), and ... report on Genetic Technologies can be accessed at ... the NASDAQ Composite ended at 4,941.42, down 1.64%, ...
(Date:5/1/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... (NASDAQ: UTHR ) announced today that Roger Jeffs ... will provide an overview and update on the company,s business ... Conference in Boston, Massachusetts . ... at 3:30 PM Eastern Time, and can be accessed via ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... any tissue with the Big Blue transgenic,rodent ... Barry W. Glickman ,Centre for Environmental Health, University of ... transgenic rodent mutation,assay,* which carries the ... vector, it is easy to study mutations in male,and ...
... and efficient PCR cloning with pcmv-script PCR cloning kit ... Tim Sanchez Quinn,Lu ,Stratagene Cloning Systems, Inc. , ... cloning,strategy by introducing a new vector for ... The pcmv-script PCR,cloning kit ...
... reagent is effective with a wide variety ... ,Genetic Applications LLC , LipoTAXI ... delivery of foreign DNA into mammalian,cells. In this study, ... conditions for transfecting a reporter plasmid in three common ...
Cached Biology Technology:Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 2Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 3Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 4Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 5Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 6Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 7Mammalian Expression Vector for Efficient Cloning of PCR Fragments 2Mammalian Expression Vector for Efficient Cloning of PCR Fragments 3Mammalian Expression Vector for Efficient Cloning of PCR Fragments 4A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7,Cell Lines 2A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7,Cell Lines 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... French . Toronto (June 5, 2009) ... to announce another measure to address the H1N1 flu virus. ... network focused on pandemic vaccine evaluation. The network will strengthen ... pandemic influenza vaccine and vaccination programs. The network was ...
... may shape the human genome much more slowly than ... within and among continents, the expansions and contractions of ... heavily influenced the distribution of genetic variations in populations ... from the Howard Hughes Medical Institute, the University of ...
... EAST LANSING, Mich. A pair of Michigan ... $400,000 for their cardiovascular research projects as part of ... The money, from the National Institutes of Health ... to preserve and create jobs in Michigan while also ...
Cached Biology News:Government of Canada announces funding for research on the H1N1 flu virus 2Geography and history shape genetic differences in humans 2MSU researchers receive $400,000 in first wave of stimulus funding 2
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... off the clot from fasted Cynomolgus monkeys of mixed ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
adult...
Biology Products: